Nu Skin Enterprises Reports First Quarter Results

Rhea-AI Summary

Nu Skin Enterprises Inc. (NYSE: NUS) reported first-quarter results in line with guidance, with revenue at $417.3 million, a 13.3% decrease YoY. The Rhyz business saw a 57.5% growth. Earnings per share were $(0.01), impacted by restructuring charges. Customer and affiliate numbers declined, but new product launches showed promise. Despite challenges, the company is focused on long-term growth and shareholder value.

Positive

• Rhyz business revenue grew by 57.5% YoY, indicating strong performance in this segment.

• New product launches like ageLOC WellSpa iO, RenuSpa iO, and TRMe showed promise, contributing to future growth.

• Cost management efforts helped Nu Skin post earnings per share in the upper half of its guidance range.

Negative

• Revenue saw a 13.3% decline YoY, impacted by foreign currency headwinds.

• Customer and paid affiliate numbers decreased by 19% and 30%, respectively.

• Earnings per share were $(0.01), reflecting a decline from the prior year.

Insights

Financial Analyst

Nu Skin Enterprises' report indicates a revenue decline to $417.3 million, which is a significant 13.3% decrease from the previous year. This is partly attributed to a 3.8% foreign exchange impact. However, it is noteworthy that Rhyz, their recent business venture, has seen a year-over-year growth of 57.5%. Despite these mixed results, the company managed to achieve earnings near the upper half of their guidance. The operating margin, excluding restructuring charges, was 3.8%, down from 5.4%, indicating pressure on profitability. The increased interest expense and a high income tax rate of 148.4% (or 48.5% when excluding restructuring charges) also warrant attention as it deviates significantly from the norm and could indicate financial stress. The lack of stock repurchases this quarter compared to the previous authorization highlights a potential strategy shift or conserving cash. The outlook for the remainder of 2024 suggests challenges ahead with projected revenue declines and the impact of foreign currency fluctuations.

Market Research Analyst

The company's strategic focus on its integrated beauty, wellness and lifestyle ecosystem, alongside the introduction of new products like MYND360, is reflective of Nu Skin's adaptability. However, the decline in customer and paid affiliate numbers—19% and 30% respectively—raises concerns about the company's current market positioning and the effectiveness of its customer acquisition strategies. The retail investor should monitor the performance of the company's new product launches and its entry into the Indian market, which could provide opportunities for growth. Additionally, the emphasis on cost management and efficiency improvements suggests a proactive approach to maintaining profitability amid challenging market conditions.

Corporate Strategy Analyst

Nu Skin's commitment to business transformation during disruptive times is evident. The focus on long-term growth and the mention of aligning sales leaders around new product previews and market expansion are strategic moves that could potentially revitalize the company's performance. However, the impact of macro-economic factors and the stated challenges imply that the transformation could be a slow and challenging process. It's important for investors to consider the balance between short-term headwinds, such as reduced affiliate numbers and the foreign exchange impacts, with the long-term strategic initiatives that could secure the company's position in the competitive beauty and wellness market.

PROVO, Utah--(BUSINESS WIRE)-- Nu Skin Enterprises Inc. (NYSE: NUS) today announced first quarter results in line with guidance.

Executive Summary Q1 2024 vs. Prior-year Quarter
Revenue	$417.3 million; (13.3)% (3.8)% FX impact or $(18.2) million Rhyz revenue $62.5 million; 57.5%
Earnings Per Share (EPS)	$(0.01) or $0.09 excluding restructuring charges compared to $0.23 or $0.37 excluding restructuring charges
Customers	875,261; (19)%
Paid Affiliates	154,171; (30)% or (14)% excluding an adjustment to eligibility requirements
Sales Leaders	38,609; (12)%

“Our first quarter revenue came in at the mid-point of our guidance, negatively impacted more than anticipated by foreign currency headwinds, while our cost management efforts helped us post earnings per share in the upper half of our guide,” said Ryan Napierski, Nu Skin president and CEO. “We are continuing our business transformation efforts and making progress in developing our integrated beauty, wellness and lifestyle ecosystem. During the quarter, we again drove strong gains in our Rhyz business, growing nearly 60% year-over-year. In our Nu Skin core business, the macro-economic environment impacted affiliate and customer growth around the globe, but we are encouraged by the performance of our ageLOC WellSpa iO, RenuSpa iO and TRMe launches.

“At our annual top sales leader event, we aligned around the upcoming preview of our new MYND360 cognitive health line and saw healthy energy for the opening of India next year. We also introduced some new early affiliate rewards and top leader incentives to help drive customer acquisition and business growth. While we continue to navigate the challenges of a business transformation amid these disruptive times, we continue to evolve our strategy for both our Nu Skin and Rhyz businesses and remain focused on generating long-term growth and returning value to shareholders.”

Q1 2024 Year-over-year Operating Results
Revenue	$417.3 million compared to $481.5 million (3.8)% FX impact or $(18.2) million Rhyz revenue $62.5 million; 57.5%
Gross Margin	70.5% compared to 72.3% Nu Skin business was 76.9% compared to 76.4%
Selling Expenses	36.8% compared to 39.1% Nu Skin business was 41.7% compared to 41.7%
G&A Expenses	29.9% compared to 27.8%
Operating Margin	2.1% or 3.8% excluding restructuring charges compared to 3.3% or 5.4% excluding restructuring charges
Interest Expense	$7.3 million compared to $4.9 million
Other Income/(Expense)	$(0.4) million compared to $3.4 million
Income Tax Rate	148.4% or 48.5% excluding restructuring charges compared to 22.0%
EPS	$(0.01) or $0.09 excluding restructuring charges compared to $0.23 or $0.37 excluding restructuring charges

Stockholder Value
Dividend Payments	$3.0 million
Stock Repurchases	$0.0 million $162.4 million remaining in authorization

Q2 and Full-year 2024 Outlook
Q2 2024 Revenue	$420 to $455 million; (16)% to (9)% Approximately (4) to (3)% FX impact
Q2 2024 EPS	$0.01 to $0.10 or $0.10 to $0.20 non-GAAP
2024 Revenue	$1.73 to $1.87 billion; (12)% to (5)% Approximately (3) to (2)% FX impact
2024 EPS	$0.77 to $1.16 or $0.95 to $1.35 non-GAAP

"We continue to implement strategic measures to refine our cost structure in line with business performance and strengthen our financial outlook," said James D. Thomas, chief financial officer. "The additional efficiencies garnered from our cost-saving initiatives underscore our dedication to boosting productivity. We remain vigilant in scrutinizing all facets of our operations and prioritizing initiatives to drive revenue, amplify margins and secure our financial position. Although negative foreign currency impacted our results more than initially expected and will likely continue to do so, we are keeping our 2024 guidance numbers intact. For the second quarter, we project sequential improvement with revenue of $420 to $455 million, assuming an increased foreign currency impact, with reported earnings per share of $0.01 to $0.10 or $0.10 to $0.20 excluding restructuring charges."

Conference Call

The Nu Skin Enterprises management team will host a conference call with the investment community today at 5 p.m. (ET). Those wishing to access the webcast, as well as the financial information presented during the call, can visit the Investor Relations page on the company's website at ir.nuskin.com. A replay of the webcast will be available on the same page through May 22, 2024.

About Nu Skin Enterprises Inc.

The Nu Skin Enterprises Inc. (NYSE: NUS) family of companies includes Nu Skin and Rhyz Inc. Nu Skin is an integrated beauty and wellness company, powered by a dynamic affiliate opportunity platform, which operates in nearly 50 markets worldwide. Backed by 40 years of scientific research, the company’s products help people look, feel and live their best with brands including Nu Skin® personal care, Pharmanex® nutrition and ageLOC® anti-aging, which includes an award-winning line of beauty device systems. Formed in 2018, Rhyz is a synergistic ecosystem of consumer, technology and manufacturing companies focused on innovation within the beauty, wellness and lifestyle categories.

Important Information Regarding Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that represent the company’s current expectations and beliefs. All statements other than statements of historical fact are “forward-looking statements” for purposes of federal and state securities laws and include, but are not limited to, statements of management’s expectations regarding the macro environment and the company’s performance, growth and growth opportunities, shareholder value, productivity, product previews and launches, transformation, evolution, investments, initiatives, digital tools and initiatives, and new market expansion; projections regarding revenue, expenses, margins, tax rates, earnings per share, foreign currency fluctuations, future dividends, uses of cash, financial position and other financial items; statements of belief; and statements of assumptions underlying any of the foregoing. In some cases, you can identify these statements by forward-looking words such as “believe,” “expect,” “anticipate,” “accelerate,” “project,” “vision,” “continue,” “outlook,” “guidance,” “improve,” “will,” “would,” “could,” “may,” “might,” the negative of these words and other similar words.

The forward-looking statements and related assumptions involve risks and uncertainties that could cause actual results and outcomes to differ materially from any forward-looking statements or views expressed herein. These risks and uncertainties include, but are not limited to, the following:

• any failure of current or planned initiatives or products to generate interest among the company’s sales force and customers and generate sponsoring and selling activities on a sustained basis;
• risk that direct selling laws and regulations in any of the company’s markets, including the United States and Mainland China, may be modified, interpreted or enforced in a manner that results in negative changes to the company’s business model or negatively impacts its revenue, sales force or business, including through the interruption of sales activities, loss of licenses, increased scrutiny of sales force actions, imposition of fines, or any other adverse actions or events;
• economic conditions and events globally;
• competitive pressures in the company’s markets;
• risk that epidemics, including COVID-19 and related disruptions, or other crises could negatively impact our business;
• adverse publicity related to the company’s business, products, industry or any legal actions or complaints by the company’s sales force or others;
• political, legal, tax and regulatory uncertainties, including trade policies, associated with operating in Mainland China and other international markets;
• uncertainty regarding meeting restrictions and other government scrutiny in Mainland China, as well as negative media and consumer sentiment in Mainland China on our business operations and results;
• risk of foreign-currency fluctuations and the currency translation impact on the company’s business associated with these fluctuations;
• uncertainties regarding the future financial performance of the businesses the company has acquired;
• risks related to accurately predicting, delivering or maintaining sufficient quantities of products to support planned initiatives or launch strategies, and increased risk of inventory write-offs if the company over-forecasts demand for a product or changes its planned initiatives or launch strategies;
• regulatory risks associated with the company’s products, which could require the company to modify its claims or inhibit its ability to import or continue selling a product in a market if the product is determined to be a medical device or if the company is unable to register the product in a timely manner under applicable regulatory requirements; and
• the company’s future tax-planning initiatives, any prospective or retrospective increases in duties or tariffs on the company’s products imported into the company’s markets outside of the United States, and any adverse results of tax audits or unfavorable changes to tax laws in the company’s various markets.

The company’s financial performance and the forward-looking statements contained herein are further qualified by a detailed discussion of associated risks set forth in the documents filed by the company with the Securities and Exchange Commission. The forward-looking statements set forth the company’s beliefs as of the date that such information was first provided, and the company assumes no duty to update the forward-looking statements contained in this release to reflect any change except as required by law.

Non-GAAP Financial Measures: Constant-currency revenue change is a non-GAAP financial measure that removes the impact of fluctuations in foreign-currency exchange rates, thereby facilitating period-to-period comparisons of the company’s performance. It is calculated by translating the current period’s revenue at the same average exchange rates in effect during the applicable prior-year period and then comparing that amount to the prior-year period’s revenue. The company believes that constant-currency revenue change is useful to investors, lenders and analysts because such information enables them to gauge the impact of foreign-currency fluctuations on the company’s revenue from period to period.

Earnings per share, operating margin and income tax rate, each excluding restructuring and/or impairment charges, also are non-GAAP financial measures. Restructuring and impairment charges are not part of the ongoing operations of our underlying business. The company believes that these non-GAAP financial measures are useful to investors, lenders and analysts because removing the impact of these charges facilitates period-to-period comparisons of the company’s performance. Please see the reconciliations of these items to our earnings per share, operating margin and income tax rate calculated under GAAP, below.

The following table sets forth revenue for the three-month periods ended March 31, 2024, and 2023 for each of our reportable segments (U.S. dollars in thousands):

	Three Months Ended March 31,									Constant- Currency
	2024			2023			Change			Change
Nu Skin
Americas	$	75,031		$	101,157			(25.8)%			(20.1)%
Mainland China		61,067			67,976			(10.2)%			(6.1)%
Southeast Asia/Pacific		60,065			67,810			(11.4)%			(8.1)%
Japan		44,236			52,606			(15.9)%			(5.6)%
Europa & Africa		42,273			47,444			(10.9)%			(11.8)%
South Korea		40,963			70,324			(41.8)%			(39.3)%
Hong Kong/Taiwan		30,466			34,548			(11.8)%			(9.8)%
Nu Skin other		672			(115)			684.3%			684.3%
Total Nu Skin		354,773			441,750			(19.7)%			(15.6)%
Rhyz Investments
Manufacturing		50,302			35,767			40.6%			40.6%
Rhyz other		12,231			3,945			210.0%			210.0%
Total Rhyz Investments		62,533			39,712			57.5%			57.5%
Total	$	417,306		$	481,462			(13.3)%			(9.5)%

The following table provides information concerning the number of Customers, Paid Affiliates and Sales Leaders in our core Nu Skin business for the three-month periods ended March 31, 2024, and 2023:

	Three Months Ended March 31,
	2024			2023			Change
Customers
Americas		199,399			266,378		(25)%
Mainland China		162,239			217,101		(25)%
Southeast Asia/Pacific		93,411			117,266		(20)%
Japan		108,808			115,161		(6)%
Europe & Africa		163,481			190,313		(14)%
South Korea		100,230			120,907		(17)%
Hong Kong/Taiwan		47,693			56,410		(15)%
Total Customers		875,261			1,083,536		(19)%

Paid Affiliates
Americas		29,081			38,707		(25)%
Mainland China		24,405			24,522		—
Southeast Asia/Pacific		29,778			36,431		(18)%
Japan(1)		21,679			37,155		(42)%
Europe & Africa(1)		18,313			27,654		(34)%
South Korea(1)		20,594			40,599		(49)%
Hong Kong/Taiwan(1)		10,321			16,286		(37)%
Total Paid Affiliates		154,171			221,354		(30)%

Sales Leaders
Americas		6,616			8,242		(20)%
Mainland China		9,600			10,034		(4)%
Southeast Asia/Pacific		5,570			6,337		(12)%
Japan		6,385			5,688		12%
Europe & Africa		3,715			4,524		(18)%
South Korea		4,122			6,242		(34)%
Hong Kong/Taiwan		2,601			2,688		(3)%
Total Sales Leaders		38,609			43,755		(12)%

(1)

The March 31, 2024, number is affected by a change in eligibility requirements for receiving certain rewards within our compensation structure. We plan to implement these changes in additional segments over the next several quarters. We estimate the change in eligibility requirements resulted in a reduction of approximately 14,000; 5,000; 13,000 and 3,000 for Japan, Europe & Africa, South Korea and Hong Kong/Taiwan, respectively.

• “Customers” are persons who have purchased directly from the Company during the three months ended as of the date indicated. Our Customer numbers include members of our sales force who made such a purchase, including Paid Affiliates and those who qualify as Sales Leaders, but they do not include consumers who purchase directly from members of our sales force.
• “Paid Affiliates” are any Brand Affiliates, as well as members of our sales force in Mainland China, who earned sales compensation during the three-month period. In all of our markets besides Mainland China, we refer to members of our independent sales force as “Brand Affiliates” because their primary role is to promote our brand and products through their personal social networks.
• “Sales Leaders” are the three-month average of our monthly Brand Affiliates, as well as sales employees and independent marketers in Mainland China, who achieved certain qualification requirements as of the end of each month of the quarter.

NU SKIN ENTERPRISES, INC. Consolidated Statements of Income (Unaudited) (U.S. dollars in thousands, except per share amounts)
	Three Months Ended March 31,
	2024			2023
Revenue	$	417,306		$	481,462
Cost of sales		123,242			133,588
Gross profit		294,064			347,874
Operating expenses:
Selling expenses		153,542			188,124
General and administrative expenses		124,566			133,899
Restructuring and impairment expenses		7,134			9,787
Total operating expenses		285,242			331,810
Operating income		8,822			16,064
Interest expense		7,325			4,888
Other income (expense), net		(396)			3,412
Income before provision for income taxes		1,101			14,588
Provision for income taxes		1,634			3,212
Net (loss) income	$	(533)		$	11,376
Net (loss) income per share:
Basic	$	(0.01)		$	0.23
Diluted	$	(0.01)		$	0.23
Weighted-average common shares outstanding (000s):
Basic		49,538			49,644
Diluted		49,538			50,058

NU SKIN ENTERPRISES, INC. Consolidated Balance Sheets (Unaudited) (U.S. dollars in thousands)
	March 31, 2024			December 31, 2023
ASSETS
Current assets:
Cash and cash equivalents	$	212,532		$	256,057
Current investments		8,674			11,759
Accounts receivable, net		67,041			72,879
Inventories, net		265,100			279,978
Prepaid expenses and other		93,913			81,198
Total current assets		647,260			701,871
Property and equipment, net		422,818			432,965
Operating lease right-of-use assets		93,092			90,107
Goodwill		230,768			230,768
Other intangible assets, net		101,933			105,309
Other assets		246,044			245,443
Total assets	$	1,741,915		$	1,806,463
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$	32,237		$	43,505
Accrued expenses		247,068			260,366
Current portion of long-term debt		30,000			25,000
Total current liabilities		309,305			328,871
Operating lease liabilities		74,198			70,943
Long-term debt		453,183			478,040
Other liabilities		95,023			106,641
Total liabilities		931,709			984,495
Commitments and contingencies
Stockholders’ equity:
Class A common stock – 500 million shares authorized, $0.001 par value, 90.6 million shares issued		91			91
Additional paid-in capital		618,706			621,853
Treasury stock, at cost – 40.9 million and 41.1 million shares		(1,564,942)			(1,570,440)
Accumulated other comprehensive loss		(110,607)			(100,006)
Retained earnings		1,866,958			1,870,470
Total stockholders’ equity		810,206			821,968
Total liabilities and stockholders’ equity	$	1,741,915		$	1,806,463

NU SKIN ENTERPRISES, INC. Reconciliation of Operating Margin Excluding Impact of Restructuring to GAAP Operating Margin (in thousands, except for per share amounts)
		Three months ended March 31,
		2024			2023
Operating Income		$	8,822		$	16,064
Impact of restructuring and impairment:
Restructuring and impairment			7,134			9,787
Adjusted operating income		$	15,956		$	25,851
Operating margin			2.1%			3.3%
Operating margin, excluding restructuring impact			3.8%			5.4%
Revenue		$	417,306		$	481,462

NU SKIN ENTERPRISES, INC. Reconciliation of Effective Tax Rate Excluding Impact of Restructuring to GAAP Effective Tax Rate (in thousands, except for per share amounts)
		Three months ended March 31,
		2024			2023
Provision (benefit) for income taxes		$	1,634		$	3,212
Impact of restructuring on provision for income taxes			2,356			2,593
Provision for income taxes, excluding impact of restructuring		$	3,990		$	5,805
Income before provision for income taxes			1,101			14,588
Impact of restructuring and impairment expense:
Restructuring and impairment			7,134			9,787
Income before provision for income taxes, excluding impact of restructuring		$	8,235		$	24,375
Effective tax rate			148.4%			22.0%
Effective tax rate, excluding restructuring impact			48.5%			23.8%

NU SKIN ENTERPRISES, INC. Reconciliation of Earnings Per Share Excluding Impact of Restructuring to GAAP Earnings Per Share (in thousands, except for per share amounts)
		Three months ended March 31,
		2024			2023
Net (loss) income		$	(533)		$	11,376
Impact of restructuring and impairment expense:
Restructuring and impairment			7,134			9,787
Tax impact			(2,356)			(2,593)
Adjusted net income		$	4,245		$	18,570
Diluted earnings per share		$	(0.01)		$	0.23
Diluted earnings per share, excluding restructuring impact		$	0.09		$	0.37
Weighted-average common shares outstanding (000)			49,538			50,058

NU SKIN ENTERPRISES, INC. Reconciliation of Earnings Per Share Excluding Impact of Restructuring to GAAP Earnings Per Share
		Three months ended June 30,						Year ended December 31,
		2024 - Low-end			2024 High-end			2024 - Low-end			2024 High-end
Earnings Per Share		$	0.01		$	0.10		$	0.77		$	1.16
Impact of restructuring expense:
Restructuring			0.15			0.15			0.29			0.29
Tax impact			(0.06)			(0.05)			(0.11)			(0.10)
Adjusted EPS		$	0.10		$	0.20		$	0.95		$	1.35

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20240508284158/en/

Media: media@nuskin.com, (801) 345-6397

Investors: investorrelations@nuskin.com, (801) 345-3577

Source: Nu Skin Enterprises Inc.

FAQ

What was Nu Skin Enterprises' first quarter revenue for 2024?

Nu Skin Enterprises reported first quarter revenue of $417.3 million for 2024.

What was the percentage change in Rhyz business revenue for Nu Skin Enterprises?

The Rhyz business revenue for Nu Skin Enterprises grew by 57.5% year-over-year.

What were the earnings per share for Nu Skin Enterprises in the first quarter of 2024?

Nu Skin Enterprises reported earnings per share of $(0.01) for the first quarter of 2024.

How many customers did Nu Skin Enterprises have in the first quarter of 2024?

Nu Skin Enterprises had 875,261 customers in the first quarter of 2024.

What product launches showed promise for Nu Skin Enterprises in the first quarter of 2024?

Product launches like ageLOC WellSpa iO, RenuSpa iO, and TRMe showed promise for Nu Skin Enterprises in the first quarter of 2024.

What was the impact of foreign currency on Nu Skin Enterprises' first quarter revenue?

Foreign currency headwinds negatively impacted Nu Skin Enterprises' first quarter revenue.

What was the CEO's statement regarding Nu Skin Enterprises' first quarter performance?

Nu Skin's CEO mentioned that revenue came in at the mid-point of guidance, impacted by foreign currency headwinds, while cost management efforts helped in posting earnings per share in the upper half of the guide.